Work

Supplementary Figure 2 from Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers

Year: 2023

Type: supplementary-materials

Abstract: Blockade of EphB4-ephrin-B2 enhances response to EGFR inhibitor (cetuximab) and RT resulting in significant delay in tumor growth and enhanced survival in HNSCC PDX models. Tumor growth volumes are displayed in CUHN013 (A) and CUHN004 (B) tumors including cisplatin-RT treated groups in the absence and presence of sEphB4-HSA. Cisplatin-RT treated groups did not show any significant changes in tumor growth in the absence and presence of sEphB4-HSA in CUHN013 tumors. Survival graphs are shown for CUHN013 (C) and CUHN004 (D) tumors.

DOI: 10.1158/1078-0432.22470825

Authors: Shilpa Bhatia, Jaspreet Sharma, Sanjana Bukkapatnam, Ayman Oweida, Shelby Lennon, Andy Phan, Dallin Milner, Nomin Uyanga, Antonio Jimeno, David Raben, Hilary Somerset, Lynn Heasley, Sana D. Karam

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362406207

Cites:

Cited by:

Related to: 10